| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 20 | 2025 | 664 | 3.070 |
Why?
|
| Hypoglycemic Agents | 12 | 2025 | 250 | 2.990 |
Why?
|
| Humans | 116 | 2025 | 17314 | 1.910 |
Why?
|
| Female | 92 | 2025 | 12396 | 1.800 |
Why?
|
| Cardiovascular Diseases | 7 | 2024 | 532 | 1.680 |
Why?
|
| Middle Aged | 67 | 2025 | 7836 | 1.680 |
Why?
|
| Models, Statistical | 9 | 2016 | 170 | 1.660 |
Why?
|
| Aged | 56 | 2025 | 6084 | 1.620 |
Why?
|
| Male | 67 | 2025 | 9804 | 1.370 |
Why?
|
| Diabetes Mellitus | 10 | 2020 | 452 | 1.320 |
Why?
|
| Keratosis, Actinic | 3 | 2018 | 5 | 1.300 |
Why?
|
| Diabetes, Gestational | 4 | 2022 | 311 | 1.300 |
Why?
|
| Electronic Health Records | 10 | 2022 | 704 | 1.280 |
Why?
|
| Dementia | 4 | 2025 | 121 | 1.270 |
Why?
|
| Comparative Effectiveness Research | 5 | 2018 | 62 | 1.270 |
Why?
|
| Adult | 55 | 2025 | 7500 | 1.230 |
Why?
|
| Data Interpretation, Statistical | 5 | 2016 | 69 | 1.220 |
Why?
|
| Cohort Studies | 30 | 2025 | 2514 | 1.200 |
Why?
|
| Propensity Score | 5 | 2022 | 76 | 1.200 |
Why?
|
| Medication Adherence | 5 | 2024 | 235 | 1.190 |
Why?
|
| Fluorouracil | 2 | 2018 | 11 | 1.160 |
Why?
|
| Diphosphonates | 5 | 2020 | 63 | 1.100 |
Why?
|
| HIV Infections | 8 | 2024 | 712 | 1.030 |
Why?
|
| Algorithms | 5 | 2021 | 223 | 1.030 |
Why?
|
| Hip Fractures | 3 | 2020 | 71 | 0.990 |
Why?
|
| Risk Factors | 24 | 2024 | 3258 | 0.980 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2025 | 8 | 0.960 |
Why?
|
| Breast Neoplasms | 5 | 2024 | 969 | 0.950 |
Why?
|
| California | 33 | 2020 | 2311 | 0.950 |
Why?
|
| Aged, 80 and over | 21 | 2020 | 1925 | 0.900 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2018 | 27 | 0.890 |
Why?
|
| Outcome Assessment (Health Care) | 5 | 2016 | 215 | 0.890 |
Why?
|
| Exercise | 7 | 2020 | 515 | 0.880 |
Why?
|
| Insulin | 3 | 2022 | 188 | 0.880 |
Why?
|
| Retrospective Studies | 21 | 2025 | 2415 | 0.870 |
Why?
|
| Sarcoma, Kaposi | 2 | 2021 | 12 | 0.850 |
Why?
|
| Osteoporotic Fractures | 4 | 2020 | 40 | 0.780 |
Why?
|
| Neoplasms | 4 | 2024 | 446 | 0.760 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2021 | 63 | 0.760 |
Why?
|
| Glyburide | 1 | 2022 | 7 | 0.750 |
Why?
|
| Treatment Outcome | 15 | 2019 | 1160 | 0.740 |
Why?
|
| Asthma | 8 | 2019 | 400 | 0.720 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2018 | 22 | 0.720 |
Why?
|
| Femoral Fractures | 3 | 2020 | 23 | 0.720 |
Why?
|
| Health Promotion | 6 | 2017 | 279 | 0.700 |
Why?
|
| Young Adult | 18 | 2020 | 2465 | 0.670 |
Why?
|
| Insulin, Regular, Human | 1 | 2020 | 5 | 0.650 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2020 | 4 | 0.650 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 58 | 0.650 |
Why?
|
| Databases, Factual | 6 | 2016 | 304 | 0.620 |
Why?
|
| Albuminuria | 3 | 2014 | 35 | 0.610 |
Why?
|
| Telephone | 6 | 2017 | 150 | 0.600 |
Why?
|
| Adolescent | 23 | 2021 | 3538 | 0.590 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 24 | 0.590 |
Why?
|
| Patient-Centered Care | 2 | 2015 | 186 | 0.570 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 56 | 0.570 |
Why?
|
| Aminoquinolines | 1 | 2017 | 1 | 0.570 |
Why?
|
| Proportional Hazards Models | 12 | 2022 | 701 | 0.560 |
Why?
|
| Inflammatory Bowel Diseases | 4 | 2012 | 21 | 0.540 |
Why?
|
| Data Collection | 3 | 2014 | 238 | 0.540 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2017 | 302 | 0.520 |
Why?
|
| Confounding Factors (Epidemiology) | 6 | 2016 | 84 | 0.520 |
Why?
|
| Body Mass Index | 7 | 2021 | 937 | 0.510 |
Why?
|
| Exercise Therapy | 2 | 2015 | 72 | 0.510 |
Why?
|
| Delivery of Health Care, Integrated | 9 | 2025 | 535 | 0.500 |
Why?
|
| Emergency Service, Hospital | 3 | 2015 | 384 | 0.500 |
Why?
|
| Pregnancy | 13 | 2022 | 1463 | 0.500 |
Why?
|
| Myocardial Infarction | 2 | 2020 | 224 | 0.490 |
Why?
|
| Heart Failure | 4 | 2024 | 401 | 0.490 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2013 | 312 | 0.490 |
Why?
|
| Hospitalization | 4 | 2015 | 804 | 0.490 |
Why?
|
| Machine Learning | 1 | 2016 | 53 | 0.480 |
Why?
|
| United States | 15 | 2025 | 3866 | 0.480 |
Why?
|
| Quality of Life | 3 | 2016 | 499 | 0.470 |
Why?
|
| Bone Density Conservation Agents | 3 | 2020 | 54 | 0.460 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2016 | 89 | 0.460 |
Why?
|
| Bone Screws | 2 | 2005 | 2 | 0.460 |
Why?
|
| Fracture Fixation, Internal | 2 | 2005 | 2 | 0.460 |
Why?
|
| Walking | 1 | 2015 | 89 | 0.450 |
Why?
|
| Incidence | 11 | 2016 | 1266 | 0.450 |
Why?
|
| Inflammation | 2 | 2016 | 63 | 0.440 |
Why?
|
| Blood Glucose | 2 | 2013 | 314 | 0.440 |
Why?
|
| Infant, Newborn | 10 | 2022 | 805 | 0.430 |
Why?
|
| Osteoporosis | 3 | 2020 | 74 | 0.430 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 310 | 0.430 |
Why?
|
| Schizophrenia | 4 | 2008 | 76 | 0.430 |
Why?
|
| Depression | 4 | 2015 | 486 | 0.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 195 | 0.420 |
Why?
|
| Medical Record Linkage | 2 | 2012 | 36 | 0.410 |
Why?
|
| Diabetic Nephropathies | 1 | 2013 | 25 | 0.410 |
Why?
|
| Patient Compliance | 4 | 2014 | 277 | 0.390 |
Why?
|
| Registries | 6 | 2015 | 460 | 0.390 |
Why?
|
| Prenatal Exposure Delayed Effects | 5 | 2008 | 168 | 0.390 |
Why?
|
| Motor Activity | 4 | 2015 | 208 | 0.380 |
Why?
|
| Models, Structural | 1 | 2012 | 2 | 0.380 |
Why?
|
| Medical Records | 4 | 2017 | 91 | 0.370 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 107 | 0.370 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 97 | 0.370 |
Why?
|
| Pharmaceutical Services | 2 | 2019 | 34 | 0.370 |
Why?
|
| Self Report | 3 | 2015 | 257 | 0.360 |
Why?
|
| Time Factors | 10 | 2020 | 1039 | 0.350 |
Why?
|
| Sulfonylurea Compounds | 2 | 2025 | 25 | 0.340 |
Why?
|
| Population Surveillance | 1 | 2012 | 252 | 0.340 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2022 | 39 | 0.340 |
Why?
|
| Pregnancy Trimester, First | 2 | 2020 | 41 | 0.330 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 1151 | 0.330 |
Why?
|
| Child | 13 | 2016 | 2403 | 0.320 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 674 | 0.320 |
Why?
|
| Obesity | 3 | 2017 | 814 | 0.320 |
Why?
|
| Prospective Studies | 5 | 2024 | 1226 | 0.320 |
Why?
|
| Chronic Disease | 2 | 2019 | 397 | 0.320 |
Why?
|
| Computer Simulation | 3 | 2014 | 80 | 0.310 |
Why?
|
| Depressive Disorder | 3 | 2010 | 185 | 0.310 |
Why?
|
| Anti-HIV Agents | 4 | 2024 | 159 | 0.300 |
Why?
|
| Risk Assessment | 5 | 2020 | 1076 | 0.300 |
Why?
|
| Hypertension | 3 | 2023 | 469 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 165 | 0.290 |
Why?
|
| Observational Studies as Topic | 2 | 2021 | 47 | 0.290 |
Why?
|
| Primary Health Care | 3 | 2015 | 726 | 0.280 |
Why?
|
| Child, Preschool | 9 | 2021 | 1380 | 0.280 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 11 | 0.280 |
Why?
|
| Mass Screening | 3 | 2015 | 672 | 0.280 |
Why?
|
| Health Personnel | 2 | 2016 | 126 | 0.280 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2021 | 181 | 0.280 |
Why?
|
| Program Evaluation | 3 | 2015 | 205 | 0.270 |
Why?
|
| Leiomyosarcoma | 2 | 2017 | 2 | 0.260 |
Why?
|
| Morcellation | 2 | 2017 | 2 | 0.260 |
Why?
|
| Uterine Neoplasms | 2 | 2017 | 13 | 0.260 |
Why?
|
| Pregnancy Complications | 2 | 2020 | 197 | 0.260 |
Why?
|
| Substance-Related Disorders | 2 | 2013 | 425 | 0.260 |
Why?
|
| Mentoring | 2 | 2017 | 26 | 0.260 |
Why?
|
| Postal Service | 2 | 2020 | 72 | 0.260 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 6 | 0.250 |
Why?
|
| Physical Conditioning, Human | 1 | 2016 | 1 | 0.250 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.250 |
Why?
|
| Antimalarials | 1 | 2016 | 14 | 0.250 |
Why?
|
| Glucocorticoids | 1 | 2016 | 23 | 0.250 |
Why?
|
| Quality Improvement | 2 | 2015 | 188 | 0.250 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 12 | 0.250 |
Why?
|
| Sports | 1 | 2016 | 22 | 0.250 |
Why?
|
| Bone Density | 1 | 2016 | 94 | 0.250 |
Why?
|
| Patient Education as Topic | 2 | 2015 | 193 | 0.250 |
Why?
|
| Endophthalmitis | 1 | 2015 | 1 | 0.240 |
Why?
|
| Eye Infections, Bacterial | 1 | 2015 | 1 | 0.240 |
Why?
|
| Phacoemulsification | 1 | 2015 | 3 | 0.240 |
Why?
|
| Ethnic Groups | 2 | 2016 | 451 | 0.240 |
Why?
|
| Bone Transplantation | 1 | 2005 | 1 | 0.240 |
Why?
|
| Bone Substitutes | 1 | 2005 | 1 | 0.240 |
Why?
|
| Likelihood Functions | 3 | 2021 | 45 | 0.240 |
Why?
|
| Bone Nails | 1 | 2005 | 1 | 0.240 |
Why?
|
| Bone Plates | 1 | 2005 | 1 | 0.240 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 14 | 0.240 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 104 | 0.240 |
Why?
|
| Seizures | 1 | 2015 | 28 | 0.240 |
Why?
|
| Administration, Topical | 3 | 2017 | 5 | 0.240 |
Why?
|
| Intellectual Disability | 1 | 2015 | 27 | 0.240 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 109 | 0.230 |
Why?
|
| Translational Medical Research | 1 | 2015 | 33 | 0.230 |
Why?
|
| Disease Management | 3 | 2015 | 111 | 0.230 |
Why?
|
| Prediabetic State | 2 | 2015 | 52 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2012 | 29 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 25 | 0.230 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 31 | 0.230 |
Why?
|
| Spatial Analysis | 1 | 2014 | 11 | 0.230 |
Why?
|
| Regression Analysis | 5 | 2018 | 270 | 0.230 |
Why?
|
| Data Accuracy | 1 | 2015 | 24 | 0.230 |
Why?
|
| Risk Adjustment | 1 | 2014 | 19 | 0.230 |
Why?
|
| Alcoholism | 2 | 2015 | 337 | 0.220 |
Why?
|
| Socioeconomic Factors | 6 | 2016 | 605 | 0.220 |
Why?
|
| Viral Load | 4 | 2020 | 136 | 0.220 |
Why?
|
| Cardiovascular Agents | 1 | 2024 | 22 | 0.220 |
Why?
|
| Infant | 8 | 2022 | 1161 | 0.220 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2014 | 23 | 0.220 |
Why?
|
| Managed Care Programs | 4 | 2012 | 300 | 0.220 |
Why?
|
| Occupational Health Services | 2 | 2015 | 12 | 0.220 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2024 | 25 | 0.220 |
Why?
|
| Health Policy | 1 | 2015 | 109 | 0.220 |
Why?
|
| HIV | 2 | 2021 | 26 | 0.220 |
Why?
|
| Selection Bias | 2 | 2014 | 16 | 0.220 |
Why?
|
| Air Pollutants | 4 | 2010 | 54 | 0.220 |
Why?
|
| Sacrum | 1 | 2004 | 1 | 0.220 |
Why?
|
| Pelvic Bones | 1 | 2004 | 4 | 0.220 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2015 | 381 | 0.220 |
Why?
|
| Spinal Fractures | 1 | 2004 | 12 | 0.220 |
Why?
|
| Pregnancy Outcome | 2 | 2022 | 158 | 0.210 |
Why?
|
| Metformin | 2 | 2015 | 50 | 0.210 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 17 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 143 | 0.210 |
Why?
|
| Diet | 1 | 2016 | 355 | 0.210 |
Why?
|
| Causality | 2 | 2021 | 34 | 0.210 |
Why?
|
| Disease Progression | 2 | 2015 | 259 | 0.210 |
Why?
|
| Orbit | 1 | 2013 | 1 | 0.210 |
Why?
|
| Orbital Diseases | 1 | 2013 | 1 | 0.210 |
Why?
|
| Decompression, Surgical | 1 | 2013 | 1 | 0.210 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 622 | 0.210 |
Why?
|
| Thyroid Gland | 1 | 2013 | 6 | 0.210 |
Why?
|
| Logistic Models | 7 | 2015 | 879 | 0.210 |
Why?
|
| Parents | 1 | 2016 | 297 | 0.210 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2013 | 5 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 184 | 0.200 |
Why?
|
| Crohn Disease | 2 | 2011 | 12 | 0.200 |
Why?
|
| Preventive Health Services | 1 | 2014 | 147 | 0.200 |
Why?
|
| Self-Help Groups | 1 | 2013 | 27 | 0.200 |
Why?
|
| Survival Analysis | 3 | 2013 | 202 | 0.200 |
Why?
|
| HIV Protease Inhibitors | 2 | 2024 | 24 | 0.190 |
Why?
|
| Residence Characteristics | 1 | 2014 | 253 | 0.190 |
Why?
|
| Labetalol | 1 | 2022 | 9 | 0.190 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 33 | 0.190 |
Why?
|
| Azathioprine | 1 | 2011 | 1 | 0.190 |
Why?
|
| Mercaptopurine | 1 | 2011 | 1 | 0.190 |
Why?
|
| Lymphoma | 1 | 2011 | 6 | 0.190 |
Why?
|
| Glycated Hemoglobin A | 3 | 2021 | 184 | 0.180 |
Why?
|
| Insulin, Short-Acting | 1 | 2021 | 3 | 0.180 |
Why?
|
| Splenic Neoplasms | 1 | 2011 | 1 | 0.180 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2011 | 1 | 0.180 |
Why?
|
| Postoperative Complications | 3 | 2017 | 98 | 0.180 |
Why?
|
| Brain Injuries | 1 | 2011 | 14 | 0.180 |
Why?
|
| Insulin, Long-Acting | 1 | 2021 | 11 | 0.180 |
Why?
|
| Patient Participation | 3 | 2016 | 119 | 0.180 |
Why?
|
| Referral and Consultation | 2 | 2015 | 157 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 25 | 0.180 |
Why?
|
| Ozone | 3 | 2012 | 11 | 0.180 |
Why?
|
| Adolescent Behavior | 1 | 2013 | 121 | 0.180 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 42 | 0.170 |
Why?
|
| Time | 1 | 2020 | 20 | 0.170 |
Why?
|
| Sex Factors | 4 | 2015 | 603 | 0.170 |
Why?
|
| Premature Birth | 1 | 2022 | 132 | 0.170 |
Why?
|
| RNA, Viral | 2 | 2017 | 65 | 0.170 |
Why?
|
| Pharmacy | 1 | 2020 | 12 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 173 | 0.170 |
Why?
|
| Surveys and Questionnaires | 6 | 2016 | 1282 | 0.170 |
Why?
|
| Hysterectomy | 2 | 2017 | 29 | 0.170 |
Why?
|
| Prenatal Care | 2 | 2020 | 127 | 0.160 |
Why?
|
| Anus Neoplasms | 1 | 2020 | 27 | 0.160 |
Why?
|
| Biological Products | 2 | 2018 | 6 | 0.160 |
Why?
|
| Asian Americans | 2 | 2016 | 163 | 0.160 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2020 | 22 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2013 | 274 | 0.160 |
Why?
|
| Colitis, Ulcerative | 1 | 2009 | 8 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2016 | 66 | 0.150 |
Why?
|
| Probability | 2 | 2014 | 71 | 0.150 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 4 | 0.150 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 19 | 0.150 |
Why?
|
| Keratinocytes | 1 | 2018 | 5 | 0.150 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2008 | 5 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 78 | 0.150 |
Why?
|
| Age Factors | 5 | 2015 | 878 | 0.150 |
Why?
|
| Autoimmune Diseases | 2 | 2012 | 20 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 14 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2007 | 17 | 0.140 |
Why?
|
| Uterine Diseases | 1 | 2017 | 5 | 0.140 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2007 | 2 | 0.140 |
Why?
|
| Dermatologic Agents | 1 | 2017 | 1 | 0.140 |
Why?
|
| HIV-1 | 1 | 2007 | 71 | 0.130 |
Why?
|
| Hispanic Americans | 2 | 2014 | 375 | 0.130 |
Why?
|
| Cross-Sectional Studies | 5 | 2014 | 1280 | 0.130 |
Why?
|
| Weight Loss | 2 | 2017 | 294 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 243 | 0.130 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 43 | 0.130 |
Why?
|
| Health Maintenance Organizations | 3 | 2013 | 407 | 0.130 |
Why?
|
| Antihypertensive Agents | 3 | 2022 | 154 | 0.130 |
Why?
|
| Stroke | 1 | 2020 | 309 | 0.130 |
Why?
|
| Homocysteine | 1 | 2007 | 11 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 52 | 0.130 |
Why?
|
| Psychometrics | 1 | 2007 | 119 | 0.130 |
Why?
|
| Health Surveys | 2 | 2015 | 245 | 0.130 |
Why?
|
| Epidemiologic Methods | 2 | 2005 | 72 | 0.130 |
Why?
|
| African Americans | 2 | 2014 | 439 | 0.130 |
Why?
|
| Community Health Services | 1 | 2017 | 79 | 0.130 |
Why?
|
| Cognition | 1 | 2007 | 81 | 0.130 |
Why?
|
| Motivational Interviewing | 1 | 2016 | 34 | 0.130 |
Why?
|
| Comorbidity | 3 | 2015 | 560 | 0.130 |
Why?
|
| Dideoxynucleosides | 1 | 2016 | 8 | 0.130 |
Why?
|
| Diabetic Neuropathies | 1 | 2016 | 10 | 0.120 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2016 | 1 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 46 | 0.120 |
Why?
|
| Research Design | 5 | 2015 | 336 | 0.120 |
Why?
|
| Mass Media | 1 | 2015 | 15 | 0.120 |
Why?
|
| Leiomyoma | 1 | 2016 | 13 | 0.120 |
Why?
|
| Spirometry | 1 | 2015 | 66 | 0.120 |
Why?
|
| Life Style | 2 | 2015 | 316 | 0.120 |
Why?
|
| Risk | 3 | 2016 | 496 | 0.120 |
Why?
|
| Self Efficacy | 1 | 2015 | 68 | 0.120 |
Why?
|
| Health Status | 2 | 2005 | 293 | 0.120 |
Why?
|
| Electronic Mail | 1 | 2015 | 51 | 0.120 |
Why?
|
| Leisure Activities | 1 | 2005 | 34 | 0.120 |
Why?
|
| Leukotriene Antagonists | 2 | 2016 | 12 | 0.120 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2015 | 16 | 0.120 |
Why?
|
| Smoking Cessation | 1 | 2016 | 154 | 0.120 |
Why?
|
| Body Composition | 1 | 2005 | 91 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2005 | 81 | 0.120 |
Why?
|
| Mastectomy | 1 | 2005 | 35 | 0.120 |
Why?
|
| Biostatistics | 1 | 2014 | 11 | 0.110 |
Why?
|
| Fracture Healing | 2 | 2005 | 2 | 0.110 |
Why?
|
| International Classification of Diseases | 3 | 2011 | 86 | 0.110 |
Why?
|
| Motivation | 1 | 2015 | 115 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2005 | 31 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 81 | 0.110 |
Why?
|
| Epidemiologic Studies | 2 | 2012 | 29 | 0.110 |
Why?
|
| Patient Satisfaction | 2 | 2013 | 191 | 0.110 |
Why?
|
| Aging | 1 | 2005 | 160 | 0.110 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2008 | 13 | 0.110 |
Why?
|
| Achilles Tendon | 1 | 1994 | 2 | 0.110 |
Why?
|
| Tendon Injuries | 1 | 1994 | 2 | 0.110 |
Why?
|
| Bias | 4 | 2022 | 96 | 0.110 |
Why?
|
| Health Systems Plans | 1 | 2013 | 3 | 0.110 |
Why?
|
| Social Support | 1 | 2015 | 207 | 0.110 |
Why?
|
| Continental Population Groups | 1 | 2016 | 286 | 0.110 |
Why?
|
| Vital Signs | 1 | 2013 | 12 | 0.110 |
Why?
|
| Early Medical Intervention | 1 | 2013 | 10 | 0.110 |
Why?
|
| Survival Rate | 3 | 2016 | 252 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 535 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 357 | 0.100 |
Why?
|
| Office Visits | 1 | 2013 | 73 | 0.100 |
Why?
|
| Employee Incentive Plans | 1 | 2013 | 4 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 153 | 0.100 |
Why?
|
| User-Computer Interface | 1 | 2012 | 21 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 298 | 0.100 |
Why?
|
| Adalimumab | 2 | 2012 | 4 | 0.100 |
Why?
|
| Infliximab | 2 | 2012 | 6 | 0.100 |
Why?
|
| Age of Onset | 1 | 2012 | 70 | 0.100 |
Why?
|
| Absorptiometry, Photon | 2 | 2016 | 51 | 0.090 |
Why?
|
| Mohs Surgery | 1 | 2011 | 1 | 0.090 |
Why?
|
| Poisson Distribution | 2 | 2012 | 85 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 120 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2012 | 27 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2009 | 114 | 0.090 |
Why?
|
| Air Pollution | 2 | 2012 | 44 | 0.090 |
Why?
|
| Drug Utilization | 2 | 2015 | 121 | 0.090 |
Why?
|
| Environmental Exposure | 2 | 2010 | 121 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2011 | 56 | 0.090 |
Why?
|
| Health Behavior | 1 | 2013 | 346 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 17 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 1990 | 31 | 0.080 |
Why?
|
| Maternal Welfare | 1 | 2000 | 12 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2015 | 640 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2010 | 71 | 0.080 |
Why?
|
| Postoperative Care | 2 | 2013 | 17 | 0.080 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2020 | 54 | 0.080 |
Why?
|
| Epilepsy | 1 | 1989 | 13 | 0.080 |
Why?
|
| Environmental Pollution | 1 | 2008 | 4 | 0.080 |
Why?
|
| Stochastic Processes | 2 | 2021 | 2 | 0.080 |
Why?
|
| Canada | 2 | 2020 | 70 | 0.070 |
Why?
|
| Suicide | 1 | 1990 | 116 | 0.070 |
Why?
|
| Drug Prescriptions | 2 | 2020 | 146 | 0.070 |
Why?
|
| Twins | 1 | 1998 | 11 | 0.070 |
Why?
|
| Mental Recall | 1 | 1998 | 29 | 0.070 |
Why?
|
| Methotrexate | 1 | 2018 | 3 | 0.070 |
Why?
|
| Lung | 1 | 2008 | 60 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2020 | 82 | 0.070 |
Why?
|
| Educational Status | 1 | 1998 | 177 | 0.070 |
Why?
|
| Social Class | 1 | 1998 | 116 | 0.070 |
Why?
|
| Terminally Ill | 1 | 2007 | 9 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 64 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2013 | 1098 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 342 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2007 | 52 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 55 | 0.060 |
Why?
|
| Reference Values | 1 | 2016 | 87 | 0.060 |
Why?
|
| Interleukins | 1 | 2016 | 2 | 0.060 |
Why?
|
| Lisinopril | 1 | 2016 | 4 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2008 | 149 | 0.060 |
Why?
|
| International Normalized Ratio | 1 | 2016 | 21 | 0.060 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2016 | 33 | 0.060 |
Why?
|
| China | 1 | 2016 | 132 | 0.060 |
Why?
|
| Glucose | 1 | 2016 | 31 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 437 | 0.060 |
Why?
|
| Creatinine | 1 | 2016 | 66 | 0.060 |
Why?
|
| Inservice Training | 1 | 2015 | 14 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 58 | 0.060 |
Why?
|
| Injections, Intraocular | 1 | 2015 | 1 | 0.060 |
Why?
|
| Aminoglycosides | 1 | 2015 | 3 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 4 | 0.060 |
Why?
|
| Outpatients | 2 | 2019 | 101 | 0.060 |
Why?
|
| Cephalosporins | 1 | 2015 | 6 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2015 | 5 | 0.060 |
Why?
|
| Ankle | 1 | 2005 | 2 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2005 | 3 | 0.060 |
Why?
|
| Foot | 1 | 2005 | 4 | 0.060 |
Why?
|
| Precipitating Factors | 1 | 2015 | 2 | 0.060 |
Why?
|
| Remission Induction | 1 | 2025 | 26 | 0.060 |
Why?
|
| Diabetes Complications | 2 | 2021 | 105 | 0.060 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 49 | 0.060 |
Why?
|
| Warfarin | 1 | 2016 | 72 | 0.060 |
Why?
|
| Leadership | 1 | 2015 | 35 | 0.060 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2005 | 13 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 38 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2016 | 163 | 0.060 |
Why?
|
| Biomarkers | 1 | 2016 | 307 | 0.060 |
Why?
|
| Postmenopause | 1 | 2016 | 248 | 0.060 |
Why?
|
| Behavior Control | 1 | 2014 | 4 | 0.060 |
Why?
|
| Length of Stay | 1 | 2005 | 171 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2014 | 86 | 0.060 |
Why?
|
| Physicians | 1 | 2015 | 117 | 0.060 |
Why?
|
| Ilium | 1 | 2004 | 1 | 0.050 |
Why?
|
| Deductibles and Coinsurance | 1 | 2014 | 31 | 0.050 |
Why?
|
| Equipment Design | 1 | 2004 | 9 | 0.050 |
Why?
|
| Radiography | 1 | 2004 | 36 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 104 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2013 | 20 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 33 | 0.050 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2013 | 25 | 0.050 |
Why?
|
| Overweight | 2 | 2016 | 266 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2023 | 55 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 4 | 0.050 |
Why?
|
| Etanercept | 1 | 2012 | 4 | 0.050 |
Why?
|
| Pharmacoepidemiology | 1 | 2022 | 18 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 65 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 29 | 0.050 |
Why?
|
| Methyldopa | 1 | 2022 | 6 | 0.050 |
Why?
|
| Nifedipine | 1 | 2022 | 7 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2022 | 19 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 14 | 0.050 |
Why?
|
| Colectomy | 1 | 2012 | 31 | 0.050 |
Why?
|
| Mortality | 1 | 2012 | 116 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2011 | 24 | 0.050 |
Why?
|
| Boston | 1 | 2021 | 28 | 0.050 |
Why?
|
| Femur | 1 | 2020 | 10 | 0.040 |
Why?
|
| Patient Selection | 2 | 2008 | 176 | 0.040 |
Why?
|
| Hawaii | 1 | 2020 | 58 | 0.040 |
Why?
|
| Immunosuppression | 1 | 2020 | 6 | 0.040 |
Why?
|
| Viremia | 1 | 2020 | 9 | 0.040 |
Why?
|
| Ideal Body Weight | 1 | 2020 | 10 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2012 | 257 | 0.040 |
Why?
|
| Thinness | 1 | 2020 | 31 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 24 | 0.040 |
Why?
|
| Gestational Age | 1 | 2020 | 112 | 0.040 |
Why?
|
| Linear Models | 2 | 2011 | 206 | 0.040 |
Why?
|
| European Continental Ancestry Group | 1 | 2011 | 476 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2009 | 6 | 0.040 |
Why?
|
| Patient Portals | 1 | 2019 | 23 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 203 | 0.040 |
Why?
|
| Hemoglobinometry | 1 | 2008 | 3 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2009 | 231 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 2008 | 29 | 0.040 |
Why?
|
| Infant, Premature, Diseases | 1 | 2008 | 16 | 0.040 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 100 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 2007 | 6 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2007 | 12 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 212 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2017 | 7 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 8 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 225 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 5 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 75 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 89 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2017 | 49 | 0.030 |
Why?
|
| Observation | 1 | 2007 | 20 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 43 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 4 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 120 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2007 | 17 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 91 | 0.030 |
Why?
|
| Child of Impaired Parents | 1 | 2007 | 27 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 529 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 211 | 0.030 |
Why?
|
| Psychotic Disorders | 1 | 2007 | 49 | 0.030 |
Why?
|
| Automation | 1 | 2016 | 25 | 0.030 |
Why?
|
| Uterine Myomectomy | 1 | 2016 | 1 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2016 | 25 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2005 | 7 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 123 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 176 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 107 | 0.030 |
Why?
|
| Anthropometry | 1 | 2005 | 60 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 4 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2015 | 4 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 59 | 0.030 |
Why?
|
| Colorado | 1 | 2016 | 164 | 0.030 |
Why?
|
| Tetrazoles | 1 | 2015 | 15 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 31 | 0.030 |
Why?
|
| Drug Costs | 1 | 2015 | 32 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2005 | 21 | 0.030 |
Why?
|
| Cost Sharing | 1 | 2015 | 28 | 0.030 |
Why?
|
| Prevalence | 1 | 2007 | 840 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 53 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 84 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2015 | 170 | 0.030 |
Why?
|
| Casts, Surgical | 1 | 1994 | 1 | 0.030 |
Why?
|
| Shoes | 1 | 1994 | 1 | 0.030 |
Why?
|
| Suture Techniques | 1 | 1994 | 1 | 0.030 |
Why?
|
| Rupture | 1 | 1994 | 2 | 0.030 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 1994 | 2 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 1994 | 3 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 64 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2013 | 54 | 0.020 |
Why?
|
| Professional-Patient Relations | 1 | 2013 | 48 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 13 | 0.020 |
Why?
|
| Marital Status | 1 | 2011 | 20 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 8 | 0.020 |
Why?
|
| New Jersey | 1 | 2011 | 4 | 0.020 |
Why?
|
| Tennessee | 1 | 2011 | 6 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2011 | 26 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 32 | 0.020 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2011 | 3 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2011 | 34 | 0.020 |
Why?
|
| Medicare | 1 | 2011 | 192 | 0.020 |
Why?
|
| Medicaid | 1 | 2011 | 189 | 0.020 |
Why?
|
| Inhalation Exposure | 1 | 2008 | 5 | 0.020 |
Why?
|
| Skin Tests | 1 | 2008 | 2 | 0.020 |
Why?
|
| Epidemiological Monitoring | 1 | 2008 | 24 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2008 | 27 | 0.020 |
Why?
|
| Fathers | 1 | 1998 | 9 | 0.020 |
Why?
|
| Pregnancy Trimesters | 1 | 2008 | 29 | 0.020 |
Why?
|
| Occupations | 1 | 1998 | 15 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2008 | 67 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 390 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2008 | 66 | 0.020 |
Why?
|
| Terminal Care | 1 | 2007 | 45 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 1 | 0.020 |
Why?
|
| Gene Expression | 1 | 2006 | 23 | 0.020 |
Why?
|
| Software | 1 | 2006 | 19 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 14 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2008 | 259 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2005 | 12 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 271 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 367 | 0.010 |
Why?
|